title: Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
abstract: Telavancin was tested against a worldwide collection of Gram-positive pathogens (967) isolated from bone and joint infections (BJI). Most BJI isolates were from the United States (US) (49.9%) followed by Europe (26.4%), Latin America (LATAM; 14.4%), and Asia-Pacific (APAC; 9.3%). Organisms were tested by broth microdilution susceptibility methods. S. aureus (66.4%; range of 48.9% in APAC to 71.2% in LATAM) was the most common pathogen and had a 35.7% methicillin resistance (MRSA) rate and telavancin MIC50/90of 0.03/0.06μg/mL (100% susceptible). MRSA isolates that were daptomycin resistant (0.2%) were telavancin susceptible. CoNS (12.1% of BJI) had telavancin MIC50/90at 0.06/0.06μg/mL, and 13.7% were teicoplanin resistant. Enterococci had telavancin MIC50/90at 0.12/0.25μg/mL, but telavancin inhibited vancomycin-susceptible isolates at ≤0.25μg/mL. All streptococci were telavancin susceptible (MIC90, 0.03-0.06μg/mL). The in vitro results presented here warrant further investigations to access the role of telavancin for BJI/osteomyelitis treatment caused by Gram-positive cocci.
authors.affiliation: JMI Laboratories, North Liberty, Iowa, US.
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
authors.affiliation: JMI Laboratories, North Liberty, Iowa, US.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
authors.affiliation: JMI Laboratories, North Liberty, Iowa, US.
authors.forename: Mariana
authors.initials: M
authors.lastname: Castanheira
authors.affiliation: JMI Laboratories, North Liberty, Iowa, US.
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
authors.affiliation: Theravance Biopharma US, Inc., South San Francisco, CA, US.
authors.forename: Jennifer I
authors.initials: JI
authors.lastname: Smart
authors.affiliation: JMI Laboratories, North Liberty, Iowa, US. Electronic address: rodrigo-mendes@jmilabs.com.
authors.forename: Rodrigo E
authors.initials: RE
authors.lastname: Mendes
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001208:Asia; D016983:Enterococcus / Q000187:drug effects* / Q000302:isolation & purification; D005060:Europe; D006801:Humans; D007843:Latin America; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D010019:Osteomyelitis / Q000382:microbiology; D013291:Streptococcus / Q000187:drug effects* / Q000302:isolation & purification; D014481:United States
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin
keywords: Gram-positive; Osteomyelitis; S. aureus; Surveillance; Telavancin